New Prague, Minnesota--(Newsfile Corp. - November 20, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that it will participate in NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference being held at Florida Atlantic University in Boca Raton, Florida, on Wednesday, December 3, 2025. Jim Cunniff, Electromed's President and Chief Executive Officer, will present at 5:00 pm ET.
A video webcast of the presentation will be available the following day on Electromed's website Events & Presentations, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: www.nobleconference.com.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
About Noble Capital Markets, Inc.
Established in 1984, Noble Capital Markets (Noble) is an SEC / FINRA registered full-service broker-dealer offering investment/merchant banking and advisory services, with an award-winning research team, and a proprietary research distribution platform (Channelchek). Noble provides middle-market expertise to entrepreneurs, corporations, financial sponsors, and investors. In addition to its large scale in-person conference, NobleCon, Noble hosts multi-sector virtual conferences throughout the year. Over the more than 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com | www.nobleconference.com.
Brad Nagel, Chief Financial Officer
(952) 758-9299
This email address is being protected from spambots. You need JavaScript enabled to view it.
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$27.68 |
| Daily Change: | 1.26 4.77 |
| Daily Volume: | 64,627 |
| Market Cap: | US$230.850M |
November 12, 2025 August 26, 2025 April 03, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load